Patents by Inventor Jeffrey A. KNAUF

Jeffrey A. KNAUF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TSHR MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20240415888
    Abstract: The present technology provides anti-Thyroid Stimulating Hormone Receptor (TSHR) multi-specific (e.g., bispecific) immunoglobulin-related compositions and methods of using the same to treat TSHR-associated pathologies including, but not limited to, thyroid cancers, T-ALL (T lineage acute lymphoblastic leukemia), multiple myeloma and Grave's disease. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: October 17, 2022
    Publication date: December 19, 2024
    Inventors: Nai-Kong V. Cheung, James A. Fagin, Hong Fen Guo, Yuchen Jin, Jeffrey Knauf, Gnana Krishnamoorthy, Yiwei Liu, Brian Santich
  • TREATMENT OF H-RAS-DRIVEN TUMORS
    Publication number: 20220202806
    Abstract: The present disclosure describes a compositions and methods for treatment of Hras-driven cancers.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 30, 2022
    Inventors: James A. FAGIN, Jeffrey A. KNAUF, Brian R. UNTCH
  • Treatment of H-Ras-driven tumors
    Patent number: 11331312
    Abstract: The present disclosure describes a compositions and methods for treatment of Hras-driven cancers. Administration of a farnesyltransferase inhibitor, for example, tipifarnib, alone or in combination with a MEK inhibitor can reduce tumor size and tumor growth in cancers such as poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC).
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: May 17, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: James A. Fagin, Jeffrey A. Knauf, Brian R. Untch
  • TREATMENT OF H-RAS-DRIVEN TUMORS
    Publication number: 20170042881
    Abstract: The present disclosure describes a compositions and methods for treatment of Hras-driven cancers. Administration of a farnesyltransferase inhibitor, for example, tipifarnib, alone or in combination with a MEK inhibitor can reduce tumor size and tumor growth in cancers such as poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC).
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: James A. FAGIN, Jeffrey A. KNAUF, Brian R. UNTCH
  • Organic Cooling Medium And Its Uses
    Publication number: 20080093579
    Abstract: An organic cooling medium that includes a cooling agent and which may further include a chloride salt. The cooling agent selected from the group consisting of carbohydrates, sugar alcohols, glycosides, maltodextrins, hydrogenated maltodextrins, starch hydrolysates, hydrogenated starch hydrolysates, non-toxic oils, and mixtures thereof.
    Type: Application
    Filed: August 30, 2007
    Publication date: April 24, 2008
    Inventor: Jeffrey Knauf
  • Organic cooling medium and its uses
    Publication number: 20050184272
    Abstract: An organic cooling medium that includes a cooling agent and which may further include a chloride salt. The cooling agent selected from the group consisting of carbohydrates, sugar alcohols, glycosides, maltodextrins, hydrogenated maltodextrins, starch hydrolysates, hydrogentated starch hydrolysates, non-toxic oils, and mixtures thereof.
    Type: Application
    Filed: September 2, 2004
    Publication date: August 25, 2005
    Inventor: Jeffrey Knauf